Innovent Biologics Inc, a Chinese biotech firm backed by Singapore’s Temasek Holdings, has filed for an initial public offering (IPO) in Hong Kong, which, for the first time, allows pre-revenue biotech firms to list.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
